FAP and neoplasm: FAP-RLT has gained prominence, demonstrating feasibility, safety, and early signs of efficacy across various tumor types, with ongoing phase 1 and 2 trials, while the impact of FAP-radioligands on tumor microenvironment components, particularly fibroblasts, requires further investigation to understand the mechanisms and optimize the therapeutic outcomes, emphasizing the need for a comprehensive understanding at the molecular and cellular levels.